ZX-J-19L
Based on 1 Customer Validation
ZX-J-19L is a CyPJ inhibitor with inhibitory activity against a variety of tumor cell lines. ZX-J-19L inhibits the growth of human liver cancer cells, human breast cancer cells, ovarian cancer cells and prostate cancer cells in vitro. ZX-J-19L can be used for tumor research.
For research use only. We do not sell to patients.
- Purity : 99.41%
- CAS No.: 1346754-06-0
- Formula: C24H21N3O
- Molecular Weight:367.44
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Cyclophilin Isoforms
More
Biological Activity
Description
In Vitro
ZX-J-19L (1.0-250 µM; 48 h) inhibits the proliferation of human hepatocellular carcinoma SK-HEP1 and QGY cells[1].
ZX-J-19L (20 µM; 48 h) inhibits the growth of human breast cancer (HCC1954, BT474, MDA-MB468), ovarian cancer (SKOV3) and prostate cancer (PC3, LNCaP) cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human hepatocellular carcinoma (HCC) SK-HEP1/QGY cells
-
Concentration:1.0, 5.0, 10, 50, 250 µM
-
Incubation Time:48 h
-
Result:Inhibited SK-HEP1 cell growth with an IC50 of 3.512 µM.
Inhibited QGY cell growth with an IC50 of 21.353 µM.
-
Cell Line:human breast cancer HCC1954, BT474, MDA-MB468 cells; human ovarian cancer SKOV3 cells; human prostate cancer PC3, LNCaP cells
-
Concentration:20 µM
-
Incubation Time:48 h
-
Result:Inhibited HCC1954 cell growth by 91.258%.
Inhibited BT474 cell growth by 90.963%.
Inhibited MDA-MB468 cell growth by 90.849%.
Inhibited SKOV3 cell growth by 90.919%.
Inhibited PC3 cell growth by 91.039%.
Inhibited LNCaP cell growth by 91.038%.
Chemical Information
-
CAS No. 1346754-06-0
-
Appearance Solid
-
Molecular Weight 367.44
-
Formula C24H21N3O
-
Color White to off-white
-
SMILES
O=C(CCC)NC1=CC=C2N=C(C(C3=CC=CC=C3)=NC2=C1)C4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (272.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7215 mL | 13.6077 mL | 27.2153 mL | 68.0383 mL |
| 5 mM | 0.5443 mL | 2.7215 mL | 5.4431 mL | 13.6077 mL | |
| 10 mM | 0.2722 mL | 1.3608 mL | 2.7215 mL | 6.8038 mL | |
| 15 mM | 0.1814 mL | 0.9072 mL | 1.8144 mL | 4.5359 mL | |
| 20 mM | 0.1361 mL | 0.6804 mL | 1.3608 mL | 3.4019 mL | |
| 25 mM | 0.1089 mL | 0.5443 mL | 1.0886 mL | 2.7215 mL | |
| 30 mM | 0.0907 mL | 0.4536 mL | 0.9072 mL | 2.2679 mL | |
| 40 mM | 0.0680 mL | 0.3402 mL | 0.6804 mL | 1.7010 mL | |
| 50 mM | 0.0544 mL | 0.2722 mL | 0.5443 mL | 1.3608 mL | |
| 60 mM | 0.0454 mL | 0.2268 mL | 0.4536 mL | 1.1340 mL | |
| 80 mM | 0.0340 mL | 0.1701 mL | 0.3402 mL | 0.8505 mL | |
| 100 mM | 0.0272 mL | 0.1361 mL | 0.2722 mL | 0.6804 mL |
ZX-J-19L Related Classifications
HY-182397 Related Classifications
Powered by Bioz